Recruiting at 1 site No phase Pain, Chronic

Clinical trial for Pain, Chronic

Official title VR and Cooled Genicular Nerve Radio Frequency Ablation for Chronic Knee Pain

ClinicalTrials.gov ID: NCT06336447

What this study is testing

What it's testing
The study wants to see if using virtual reality as a distraction during the procedure lowers pain and improves pain and function after one month.
Who it's for
Adults who have chronic knee pain and are scheduled for a genicular nerve radiofrequency ablation.
What's involved
Participants will receive either sedation alone or sedation plus a virtual reality headset during the procedure, and will have pain and function measured during and after the treatment.
Time commitment
The study lasts about one month, with visits for the procedure and a follow‑up assessment one month later.

A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.

Who can take part

Ages 18 and older

You may be able to join if

  • Patients undergoing genicular RFA will be eligible for inclusion in the study
  • Patients with knee pain, baseline average of \> 4/10
  • X-ray evidence of osteoarthritis of the knee
  • Pain duration of \>6 weeks and no previous knee surgeries
  • Patients will also only be included who have never undergone a RFA on the affected knee

You likely can't join if

  • Individuals who do not have evidence of osteoarthritis on X-ray,
  • Secondary gain expected to influence treatment outcomes
  • Poorly controlled psychiatric condition that could affect outcome (e.g. active substance abuse) or impose a barrier to participation
  • Chronic opioid use and anticoagulation therapy that cannot be stopped and could warrant a different treatment approach (e.g. phenol ablation)
  • Severe motion sickness
  • Seizure disorder
See the full eligibility criteria
Who can join
  • Patients undergoing genicular RFA will be eligible for inclusion in the study
  • Patients with knee pain, baseline average of \> 4/10
  • X-ray evidence of osteoarthritis of the knee
  • Pain duration of \>6 weeks and no previous knee surgeries
  • Patients will also only be included who have never undergone a RFA on the affected knee
What rules you out
  • Individuals who do not have evidence of osteoarthritis on X-ray,
  • Secondary gain expected to influence treatment outcomes
  • Poorly controlled psychiatric condition that could affect outcome (e.g. active substance abuse) or impose a barrier to participation
  • Chronic opioid use and anticoagulation therapy that cannot be stopped and could warrant a different treatment approach (e.g. phenol ablation)
  • Severe motion sickness
  • Seizure disorder
  • Vision loss
  • Pregnant
  • Nursing

The study team makes the final eligibility decision.

Where it is enrolling

  • Chicago, Illinois, United States

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.

Where is this trial taking place?

This study is enrolling now at Chicago, Illinois, United States. Enter your location above to see the nearest enrolling site and check your eligibility.

Explore other conditions

BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.